{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Washington+D.C.&page=7&state=District+of+Columbia", "query": { "state": "District of Columbia", "city": "Washington D.C.", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 182, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Washington+D.C.&page=8&state=District+of+Columbia&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Washington+D.C.&page=6&state=District+of+Columbia&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T20:05:40.099Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01322490", "title": "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "GM-CSF Placebo", "type": "OTHER" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1297, "start_date": "2011-11-28", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 84, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322490" }, { "nct_id": "NCT05754957", "title": "A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Milvexian", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14194, "start_date": "2023-04-07", "completion_date": "2026-02-06", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 162, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05754957" }, { "nct_id": "NCT06112314", "title": "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Melanoma" ], "interventions": [ { "name": "Brenetafusp", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2024-06-05", "completion_date": "2027-10-16", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 37, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06112314" }, { "nct_id": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2019-05-13", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 581, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866382" }, { "nct_id": "NCT01145495", "title": "Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-06-15", "completion_date": "2022-01-15", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 91, "location_summary": "Mountain View, California • Palo Alto, California • Lewes, Delaware + 66 more", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01145495" }, { "nct_id": "NCT01539512", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Placebo to match idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2012-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2019-05-14", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 34, "location_summary": "Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01539512" }, { "nct_id": "NCT00000811", "title": "A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Infections", "Pneumonia, Pneumocystis Carinii", "HIV Infections" ], "interventions": [ { "name": "Azithromycin", "type": "DRUG" }, { "name": "Atovaquone", "type": "DRUG" }, { "name": "Sulfamethoxazole-Trimethoprim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "18 Months", "sex": "ALL", "summary": "3 Months to 18 Months" }, "enrollment_count": 690, "start_date": null, "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000811" }, { "nct_id": "NCT01191801", "title": "Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "vosaroxin + cytarabine", "type": "DRUG" }, { "name": "placebo + cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunesis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 711, "start_date": "2010-12-17", "completion_date": "2017-03-01", "has_results": true, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 38, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 31 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191801" }, { "nct_id": "NCT00008281", "title": "Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 121, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 100 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008281" }, { "nct_id": "NCT06008756", "title": "Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arteriosclerosis", "Hypercholesterolaemia" ], "interventions": [ { "name": "Enlicitide Decanoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14550, "start_date": "2023-10-09", "completion_date": "2031-11-29", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-01T20:05:40.099Z", "location_count": 132, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008756" } ] }